HLA-DQ Genetic Test: Celiac Disease, Autoimmune Risk, and Results

An HLA-DQ genetic test identifies inherited HLA-DQA1 and HLA-DQB1 alleles that pair to form HLA-DQ class II immune molecules. It is most commonly used to assess whether a person has the genetic background required for celiac disease, but it can also support transplant matching and specialized evaluation of type 1 diabetes, narcolepsy, drug reactions, and other immune conditions. The result is not a simple positive or negative diagnosis. HLA-DQ2 and HLA-DQ8 are common in the general population, so finding them shows susceptibility rather than disease. Their absence makes celiac disease very unlikely when the test fully covers recognized risk combinations. HLA-DQ typing does not replace celiac antibody tests or intestinal biopsy when those are clinically needed, and it should not be used alone to start a gluten-free diet. High-resolution testing may report separate DQA1 and DQB1 alleles, which must be paired correctly to identify the expressed molecule. Interpretation depends on the clinical question, ancestry, family history, current diet, antibody findings, and sometimes comparison with a transplant donor.

• HLA-DQ testing identifies DQA1 and DQB1 alleles that form immune-presenting DQ molecules.
• HLA-DQ2 or HLA-DQ8 positivity supports genetic susceptibility to celiac disease but does not diagnose it.
• A well-performed negative DQ2/DQ8 result makes celiac disease very unlikely, especially when rare permissive combinations are also assessed.
• The test works while a person is gluten-free, unlike celiac antibody and biopsy findings that may normalize after gluten avoidance.
• No fasting is needed; blood, saliva, or a cheek swab can provide DNA.
• HLA-DQ risk results should not be used alone to predict type 1 diabetes, narcolepsy, or other autoimmune disease.

Table of Contents

• What HLA-DQ Testing Measures
• Why the Test Is Ordered
• How HLA-DQ Testing Is Performed
• Understanding HLA-DQ Results
• HLA-DQ and Celiac Disease
• Other Autoimmune and Immune Associations
• HLA-DQ in Transplantation
• Limitations and Next Steps

What HLA-DQ Testing Measures

HLA-DQ is a class II human leukocyte antigen. It is made from an alpha chain encoded by HLA-DQA1 and a beta chain encoded by HLA-DQB1. These proteins pair on antigen-presenting cells and display peptide fragments to CD4 T cells. The peptides and the shape of the HLA-DQ binding groove influence which immune responses can occur.

Each person inherits one DQA1 allele and one DQB1 allele from each biological parent. The alleles inherited together on one chromosome form a haplotype. Alpha and beta chains encoded on the same chromosome can pair in cis. In some people, chains from opposite chromosomes can pair in trans, creating additional functional HLA-DQ molecules.

A high-resolution report may list:

• HLA-DQA105:01 and HLA-DQA102:01
• HLA-DQB102:01 and HLA-DQB102:02

Those allele names must be translated into clinically recognized heterodimers. For celiac disease, HLA-DQ2.5 usually refers to DQA105 paired with DQB102. HLA-DQ2.2 usually refers to DQA102:01 paired with DQB102:02. HLA-DQ8 generally refers to DQA103 paired with DQB103:02.

HLA-DQ results are not classified as pathogenic or benign variants. They are common immune alleles whose significance depends on a particular exposure or disease mechanism. DQ2.5 efficiently presents deamidated gluten peptides to T cells, but most people who carry DQ2.5 never develop celiac disease.

The result is lifelong. Diet, age, medication, inflammation, or disease treatment does not change inherited HLA-DQ alleles. A validated previous result can usually be reused, although the clinician should confirm that the test assessed both DQA1 and DQB1 or otherwise accurately inferred the relevant heterodimers.

A broad HLA typing test may report HLA-DQ as part of a multi-locus transplant panel. A celiac-focused test may report only DQ2, DQ8, and selected risk combinations. These tests are not always equivalent.

Why the Test Is Ordered

The most common clinical use is to help exclude celiac disease in situations where standard testing is incomplete or conflicting. HLA testing is especially useful because genotype remains detectable after a person stops eating gluten.

Doctors may order HLA-DQ testing when:

• celiac antibody tests and small-intestinal biopsy disagree
• a person began a gluten-free diet before diagnostic testing
• a gluten challenge would be difficult, risky, or strongly unwanted
• biopsy shows villous atrophy but celiac antibodies are negative
• a previous celiac diagnosis was uncertain or poorly documented
• a first-degree relative has celiac disease and family risk is being evaluated
• another condition could explain the intestinal findings
• a specialist is evaluating a rare seronegative celiac presentation

HLA-DQ is not usually the first test for a person eating gluten who has possible celiac disease. Initial testing normally includes tissue transglutaminase IgA with total IgA, followed by other serology or endoscopy as indicated. HLA typing has low positive specificity because many healthy people carry DQ2 or DQ8.

The test may also be ordered in research or specialist assessment of type 1 diabetes. Certain DQ haplotypes, especially DQ8 and DQ2, raise population risk, while others are protective. However, HLA alone cannot predict whether a child or adult will develop diabetes. Autoantibodies, glucose measures, family history, and validated screening programs are more directly relevant.

HLA-DQB1*06:02 is strongly associated with narcolepsy type 1, particularly with cataplexy and hypocretin deficiency. Because the allele is common in unaffected people, a positive result is supportive but not diagnostic. Its absence may make classic narcolepsy type 1 less likely, but sleep studies and clinical features remain essential.

Transplant teams order HLA-DQ to compare patients and donors or to identify donor-specific antibodies. Drug-hypersensitivity research may also identify DQ associations, but only validated drug–HLA pairs should guide prescribing.

How HLA-DQ Testing Is Performed

Testing uses DNA from blood, saliva, or buccal cells. No fasting is required, and eating gluten is not required. This makes genetic testing useful when a person has already been gluten-free for months or years.

Laboratory methods include targeted PCR, sequence-specific probes, Sanger sequencing, next-generation sequencing, and sometimes imputation from nearby genetic markers. Clinical diagnosis and transplant decisions should use direct, validated HLA typing rather than unconfirmed consumer imputation.

A celiac-focused assay may take one of three approaches:

1. directly type DQA1 and DQB1 alleles
2. detect the main DQ2.5, DQ2.2, and DQ8 haplotypes
3. test selected marker variants that reliably tag those haplotypes in the validated population

Direct allele typing provides the most transparent result. Marker-based assays can be accurate but may have ancestry-specific limitations or fail to identify uncommon combinations. The report should state exactly what was tested.

Turnaround time is commonly several days to two weeks. The laboratory may report “positive for HLA-DQ2.5,” “DQ8 detected,” “celiac-associated HLA present,” or a full allele list. A full allele list often needs expert translation because the clinical heterodimer depends on alpha–beta pairing.

Sample collection after an allogeneic stem cell transplant requires caution. Blood DNA may reflect the donor’s HLA-DQ type. A pre-transplant sample or non-blood tissue can be needed to determine the recipient’s original genotype. Ordinary blood transfusion is less likely to alter the result but should still be reported to the laboratory if recent or massive.

The result should include assay limitations. A test that reports only DQB1*02 may not distinguish whether the person can form DQ2.5, DQ2.2, or another heterodimer. Testing both chains is important when the clinical question requires precise risk classification.

Understanding HLA-DQ Results

HLA-DQ reports may be allele-based, haplotype-based, or phenotype-based. The wording can look very different even when two laboratories found the same biology.

HLA-DQ pattern	Typical allele combination	General interpretation
DQ2.5	DQA1*05 with DQB1*02	Strongest and most common celiac susceptibility heterodimer
DQ2.2	DQA1*02:01 with DQB1*02:02	Lower average susceptibility than DQ2.5 but compatible with celiac disease
DQ8	DQA1*03 with DQB1*03:02	Established celiac and type 1 diabetes susceptibility heterodimer
DQ7-related permissive pattern	Selected DQA1*05/DQB1*03 combinations	May contribute to rare celiac-compatible genotypes depending on pairing and laboratory definition

A positive celiac-associated result means the person has a necessary or permissive genetic background. It does not show active intestinal inflammation, gluten exposure, antibody production, or villous injury. Positive predictive value is low because DQ2 or DQ8 occurs in roughly 30% to 50% of many populations, while celiac disease affects about 1% overall.

A negative result means the main susceptibility heterodimers were not found. When the assay includes DQ2.5, DQ2.2, DQ8, and relevant rare combinations, celiac disease becomes extremely unlikely. A negative result can prevent an unnecessary gluten challenge or prompt investigation for another cause of symptoms or villous atrophy.

An “inconclusive” result may reflect incomplete allele resolution, uncertain alpha–beta phase, poor sample quality, or an uncommon allele combination. The next step is usually full high-resolution DQA1 and DQB1 typing rather than assuming the patient is positive or negative.

Gene dose may appear in the report. Two copies of DQB1*02 or two DQ2.5 haplotypes generally confer higher celiac susceptibility than one copy. Gene dose is not a diagnosis and does not establish disease severity for an individual. It may help explain relative risk in research and selected family counseling.

HLA-DQ and Celiac Disease

Celiac disease develops when dietary gluten triggers an adaptive immune response that damages the small-intestinal lining in a genetically susceptible person. Tissue transglutaminase modifies gluten peptides, allowing them to bind efficiently to DQ2 or DQ8. CD4 T cells then drive inflammation and autoantibody production.

More than 90% of people with celiac disease carry DQ2.5, while most of the remainder carry DQ8, DQ2.2, or another compatible combination. This near-necessity creates a high negative predictive value. The test is far better at ruling celiac disease out than proving it in.

Useful situations include:

• Already gluten-free: HLA remains accurate when tissue transglutaminase antibodies and biopsy may have normalized.
• Conflicting tests: A negative HLA result argues strongly against celiac disease when serology or histology is uncertain.
• Seronegative villous atrophy: Positive HLA keeps celiac disease in the differential, but infections, medications, immune disorders, inflammatory disease, and other enteropathies must be evaluated.
• Questionable historical diagnosis: Negative HLA can challenge a label made without adequate testing.
• Before gluten challenge: Negative HLA can spare a person from reintroducing gluten when celiac disease is effectively excluded.

A positive result does not justify a gluten-free diet by itself. Removing gluten before completing diagnosis can make serology and biopsy less informative, add cost and social burden, and obscure another disease. People who are eating gluten and have symptoms should usually complete standard testing before changing diet.

For someone already gluten-free with a positive HLA result, the next step depends on how important a formal diagnosis is and how severe previous reactions were. A supervised gluten challenge may be considered, often using a defined daily gluten amount for several weeks followed by serology and sometimes biopsy. The exact protocol belongs with a gastroenterologist because age, symptoms, pregnancy, anemia, and other medical factors matter.

Family members of a patient with celiac disease have higher risk. HLA testing can identify relatives who are unlikely ever to develop celiac disease and therefore may not need repeated serology. Relatives with DQ2 or DQ8 remain susceptible and may need symptom-based or periodic antibody testing, but they should not avoid gluten solely because of genotype.

The separate HLA-DQ2 and HLA-DQ8 test focuses specifically on this celiac interpretation.

Other Autoimmune and Immune Associations

HLA-DQ has major effects on type 1 diabetes susceptibility. The high-risk DR3-DQ2 and DR4-DQ8 haplotypes account for a large portion of inherited HLA risk in people of European ancestry. Children who inherit both can have substantially higher relative risk than the general population. Absolute risk still depends on family history, ancestry, non-HLA genes, and the development of islet autoantibodies.

HLA-DQ testing is not a standard diagnostic test for symptomatic diabetes. Diabetes is diagnosed with glucose and hemoglobin A1c criteria, and autoimmune classification uses antibodies such as GAD65, IA-2, ZnT8, and insulin autoantibodies. In research or structured screening, HLA can identify groups for closer follow-up, but broad population testing can create anxiety without changing care.

DQB1*06:02 is present in most people with narcolepsy type 1, but it also occurs in a substantial minority of the general population. A positive result has low specificity. Diagnosis requires excessive daytime sleepiness, cataplexy assessment, polysomnography, multiple sleep latency testing, and sometimes cerebrospinal fluid hypocretin measurement.

HLA-DQ alleles are associated with autoimmune hepatitis, multiple sclerosis, rheumatoid arthritis, thyroid autoimmunity, and other conditions, often through haplotypes that include HLA-DR. The allele may be a marker for the linked haplotype rather than the direct causal factor. Effect sizes and relevant alleles vary by ancestry.

Some HLA-DQ variants influence antibody responses to vaccines or infection outcomes. These are population-level observations, not routine tests of vaccine effectiveness or immune competence. Standard vaccination and infection-prevention decisions should not be based on an HLA-DQ result unless a validated guideline specifically says so.

HLA-DQ in Transplantation

HLA-DQ contributes to both T-cell and antibody-mediated alloreactivity. In hematopoietic cell transplantation, donor selection commonly considers HLA-DQB1 after core matching at HLA-A, -B, -C, and -DRB1. HLA-DQ mismatches can affect graft-versus-host disease and other outcomes, though their weight depends on the overall match and prophylaxis platform.

Complete DQ biology requires both DQA1 and DQB1. Historical typing often focused on DQB1 because it is more polymorphic and strongly linked with DRB1. Newer work shows that alpha–beta heterodimers and trans pairing can create immunologically meaningful differences even when DQB1 alone appears matched.

In solid-organ transplantation, de novo anti-HLA-DQ antibodies are among the most common donor-specific antibodies after kidney transplantation. They have been associated with chronic antibody-mediated rejection and graft loss. Accurate donor typing helps determine whether the recipient’s antibody is truly donor-specific.

Antibody assays may report reactivity to a bead carrying a specific DQA1–DQB1 combination. Shared epitopes can produce complex patterns. Mean fluorescence intensity is semiquantitative and should not be used alone to accept or reject a donor. The transplant team combines antibody trends, crossmatch results, organ function, and biopsy findings.

An HLA-DQ allele match does not guarantee that the pair is fully compatible. Other HLA loci, donor-specific antibodies, minor antigens, non-HLA genes, and clinical factors still matter. Conversely, modern transplant strategies can permit selected HLA-DQ mismatches.

Limitations and Next Steps

HLA-DQ testing can be misleading when the assay reports only one chain, uses low resolution, or labels broad haplotypes without explaining coverage. A result that says “DQ2 negative” may not reveal whether DQ2.2 or a trans-encoded DQ2.5 molecule was assessed. The report’s methods and allele list matter.

Common errors include:

• diagnosing celiac disease from DQ2 or DQ8 positivity alone
• ruling out celiac disease from an incomplete panel
• starting a gluten-free diet before standard testing
• treating HLA risk as certainty for type 1 diabetes or narcolepsy
• comparing low-resolution transplant results with high-resolution results
• confusing an inherited HLA allele with an anti-HLA antibody
• using a consumer imputation as a definitive clinical test

When celiac disease remains possible, next steps may include total IgA, tissue transglutaminase IgA, endomysial antibody, deamidated gliadin peptide testing, endoscopy with duodenal biopsy, review of gluten intake, or supervised gluten challenge. The sequence depends on age and clinical context.

When the question is diabetes risk, clinicians may use family history, islet autoantibodies, glucose testing, and structured research or monitoring programs rather than repeating HLA typing. When the question is narcolepsy, sleep evaluation is more informative than expanded genetic panels.

For transplant use, unresolved results may require high-resolution DQA1 and DQB1 sequencing, family segregation, donor confirmation, antibody testing, or crossmatch. HLA-DQ should be interpreted as one part of the complete compatibility assessment.

A high-quality report answers the exact clinical question: whether celiac-compatible HLA is absent, which DQ heterodimers are present, whether donor and recipient match, or whether an antibody can recognize the donor. Without that context, the allele list is descriptive rather than diagnostic.

Why HLA-DQ risk cannot be reduced to one label

A report that says only “DQ2 positive” can hide important differences. Complete DQ2.5, DQ2.2, a single DQA105 allele, and a single DQB102 allele do not carry the same celiac association. DQ2.5 may also be formed by alleles inherited together on one chromosome or by complementary alleles inherited from opposite parents.

Gene dose adds another layer. Two DQB102 copies can support more DQ2.5 expression and are associated with greater celiac susceptibility than one copy. Laboratories may call this homozygous DQ2.5, DQ2.5/DQ2.2, or double-dose DQB102 depending on the haplotypes. A clinician should use the actual allele combination rather than a simplified consumer risk category.

HLA-DQ proteins also participate in many immune responses, so a disease association is not automatically specific. DQ8 can occur in celiac disease and type 1 diabetes risk haplotypes. DQB1*06:02 is associated with narcolepsy type 1 and often protects against classic childhood type 1 diabetes. The surrounding DR-DQ haplotype helps explain these different effects.

Testing relatives without overmedicalizing them

HLA testing can be efficient in a family with confirmed celiac disease. A relative who lacks compatible HLA usually does not need lifelong repeat serology. A relative who carries DQ2 or DQ8 remains susceptible but does not need a gluten-free diet, endoscopy, or repeated genetic tests solely because of the result.

Screening frequency is individualized. Symptoms, age, a first-degree relationship, type 1 diabetes, IgA deficiency, and high-risk gene dose may justify closer follow-up. Children should continue eating a normal gluten-containing diet unless celiac disease is diagnosed or another medical reason requires restriction.

Family members can inherit different haplotypes, so one sibling’s result cannot stand in for another’s. Parental allele results may help determine whether DQ2.5 is in cis or trans, but phase rarely changes immediate clinical care outside detailed risk counseling.

A laboratory genetics or immunogenetics consultation is appropriate when the allele list and the summary label appear inconsistent. Clarifying the DQA1-DQB1 pairing can prevent unnecessary diet changes or repeated testing.

References

• European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach 2025 (Guideline)
• UK NEQAS and BSHI Guideline: Laboratory Testing for HLA Genotypes Associated with Coeliac Disease 2023 (Guideline)
• Insights into coeliac disease diagnosis: a 2021–2023 literature review 2024 (Review)
• Review and Critical Appraisal of Clinical Practice Guidelines for the Diagnosis of Celiac Disease 2023 (Review)
• Diagnosis and management of celiac disease 2025 (Review)
• Gluten-Free Diet Induces Rapid Changes in Phenotype and Function of Gluten-Specific T Cells in Celiac Disease 2024 (Clinical Study)

Disclaimer

This article is educational and does not diagnose celiac disease, type 1 diabetes, narcolepsy, or transplant compatibility. HLA-DQ results need interpretation with symptoms, diet, serology, biopsy, antibody testing, and specialist assessment as appropriate. Do not begin or stop a gluten-free diet solely because of an HLA result.